Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that patient baseline characteristics and demographics from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 event driven cardiovascular outcomes clinical trial of omecamtiv mecarbil, will be published on March 28, 2020 during the American College of Cardiology 69th Annual Scientific Session
March 20, 2020
· 7 min read